MASP2 and atypical hemolytic-uremic syndrome: Indeed, therapeutic use of anti-MASP-2 antibody has demonstrable efficacy in a variety of native ischaemia models [83, 84] and Omeros OMS271, a commercial anti-MASP-2, is currently in phase 2 clinical trial for treatment of thrombotic microangiopathies (TMAs) including atypical hemolytic urea syndrome (aHUS) [85].